Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases

Cancer Journal

Volumn 6, Issue 3, 2000, Pages 179-187

  Childs, Richard W ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; KIDNEY CARCINOMA; LEUKEMIA CELL; MELANOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

CARCINOMA, RENAL CELL; GENETIC MARKERS; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; MINISATELLITE REPEATS; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033928765     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Thomas ED, Storb R, Fefer A et al. Bone-marrow transplantation. N Engl J Med 1975;292:832.
2. Thomas ED, Blume K. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 1999;5:341-346.
3. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309:1347-1353.
4. Weiden P, Flournoy N, Thomas E et al. Antileukemic effects of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979;300:1068-1073.
5. Sosman JA, Sondel PM. The graft versus leukemia effect following bone marrow transplantation: a review of laboratory and clinical data. Hematol Rev 1987;2:77.
6. Horowitz M, Gale RP, Sondel P et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1991;78:2120-2130.
7. Offit K, Burns JP, Cunningham I et al. Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T-cell depleted bone marrow transplantation. Blood 1990;75:1346.
8. Marmount A, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-2130.
9. Kolb HJ, Mittermueller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
10. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310.
11. Bearman SI. The syndrome of hepatic veno-occlusive disease after bone marrow transplantation. Blood 1995;5:363-364.
12. Atkinson K, Biggs J, Noble G et al. Preparative regimens for marrow transplantation containing busulphan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis. Bone Marrow Transplant 1987;2:385-394.
13. Weiner RS, Bortin MM, Gale RP. Risk factors associated with interstitial pneumonitis following allogeneic bone marrow transplantation for leukemia. Transplant Proc 1985;17:470-474.
14. Hartsell F, Czyzewski EA, Ghalie R et al. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide. Int J Radiat Oncol Biol Phys 1995;32:69-73.
15. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporin and methotrexate. Blood 1992;80:1838-1845.
16. Barrett AJ, Mavroudis D, Tisdale J et al. T cell depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998;21:543-551.
17. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531.
18. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
19. Slavin S, Nagler A, Naparstek E et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998;91:756.
20. Sykes M, Preffer F, McAfee S et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA mismatched bone-marrow transplantation. Lancet 1999;353:1755-1759.
21. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-3241.
22. 21a. Childs R, Epperson D, Bahceci E et al. Molecular remission of chronic myelogenous leukaemia following a non myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. Brit J Haematol 1999;107:396-400.
23. Childs R, Contentin N, Clave E et al. Reduced toxicity and transplant related mortality following nonmyeloablative allogeneic peripheral blood stem cell transplantation for malignant diseases. Blood 1999;94:393a.
24. Morecki S, Moshel Y, Gelfend Y et al. Induction of graft vs. tumor effect in a murine mammary adenocarcinoma. Int J Cancer 1997;71:59-63.
25. 23a. Eibl B, Schwaighofer H, Nachbaur D et al. Evidence of a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996;88:1501-1508.
26. Ueno NT, Rondon G, Mirza NQ et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998;16:986-993.
27. Rivoltini L, Barracchini K, Viggiano V et al. Quantitative correlation between HLA class I expression and recognition of melanoma cells by antigen-specific T lymphocytes. Cancer Res 1995;55:3149-3157.
28. Houghton AN, Meyers ML, Chapman PB et al. Medical treatment of metastatic melanoma. Surg Clin North Am 1996;76:1343-1353.
29. Elson PJ, Witte RS, Trump DI. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-7313.
30. Barth A, Wanek LA, Morton D. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995;6:118-119.
31. Mukherji B, Chakraborty NG. Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 1995;7:175-184.
32. Fairlarnb DJ. Spontaneous regression of metastatis of renal cancer. Cancer 1981;47:2102-2106.
33. Halliday GM, Patel A, Hunt M et al. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg 1995;19:352-358.
34. Melioli G, Guastella M, Semino C et al. Proliferative, phenotypic and functional and molecular characteristics of tumor-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2. Melanoma Res 1994;4:127-133.
35. Topalian SL, Solomon D, Avis FP et al. Immunotherapy of patients with advanced cancer using tunor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988;6:839-853.
36. Kradin RL, Kurnick JT, Lazarus DS et al. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989;1:577-580.
37. Rosenburg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell carcinoma using high-dose bolus interleukin 2. JAMA 1994;271:907-913.
38. Gleave ME, Elhilali M, Fradet Y et al. Interferon gamma-1b compared to placebo in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1265-1271.
39. Negrier S, Escudier B, Lasset C et al. Recombinant humam interleukin-2, recombinant human interferon alfa 2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-1278.
40. Plunkett W, Sanders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther 1991;49:239-268.
41. Childs R, Clave E, Tisdale J et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral blood progenitor cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999;17:2044-2251.